Activities of the Pharmaceutical Technology Institute of the Oswaldo Cruz Foundation with medical insecticidal and insect repellent plants

In addition to original research, Far-Manguinhos, the Pharmaceutical Division of the Brazilian Ministry of Healthïs Oswaldo Cruz Foundation (FIOCRUZ), devotes major attention to the finalising of products for use in public health campaigns or, under contract, for private industrial development. Emphasis is on standardisation, adequate supply, safety in use and efficacy. Among the products discussed in this summary of some of its activities in the chemical and pharmaceutical fields are medicinal plants Bidens pilosa, Cymbopogon citratus, Copaifera species, mentha crispa, Phyllanthus tenellus Roxb, and other Physllanthus species, insecticidal plants, Lonchocarpus urucu and Quassia amara, and the insect antifeedant plants Carapa guianensis and Peterodon emarginatus.

The official use of medicinal plants in public health

Medicinal plants are widely employed in both rural and urban Brazil, many in accordance with traditional practices that were developed by the native population or were brought to the country by immigrant peoples from Europe, Africa and Asia. Their use in official public health care requires however more than traditional knowledge. Recently published laws which will come into force by the end of the century, require that scientific evidence be brought to support the popular use, that possible toxicity, especially when chronic use is contemplated, be known to the medical profession and that the raw plant material and final formulation have a chemical composition that lies within limits that can be specific and checked by analysis. Clinical evidence of efficacy should be provided and wherever possible some indication of the mechanism of action and what components of the original plant contribute to this action, are desirable. At the same time, once a plant of given chemical compositon is approved for use, then its widespread production must be organized in such a way that suppy of a product of established quality meets the demand.

Perspective for the reproduction of antimalarial drugs in Brazil

The appears to be no chemical manufacture of antimalarial drugs is Brazil. Technology at laboratory process level has been developed for chloroquine, mefloquine, pyrimethamine and cycloquanil, but not perfected nor scaled-up, largely for economic reasons and market uncertainty. Development of primaquine has been contracted but it will run into the same difficulty. Manufacturing capacity for sulfadoxine was registred in the SDI by Roche. A project to produce artemisinine and its derivates is under way at UNICAMP-CPQBA but is hampered by low content in the plant. Proguanil could be produced easily, but apparently no attempt has been made to do so. Quinine is imported on a large scale mostly for softdrink production. Since malarial treatment falls largely within responsability of the Government health authorities, manufacture of drugs in Brazil will depend on an assured medium-term purchase order made to a potential local manufacturer, since competition in the world market is scarcelyviable at the present moment